Skip to main content

New story in Health from Time: Leaked Data From a Key Remdesivir Study Suggest the Potential Coronavirus Drug Is Not Effective



A summary of a study conducted in China on a potential COVID-19 treatment, remdesivir, was posted on the World Health Organization (WHO) website on Thursday and then removed.

The researchers responsible for the study had not approved its posting; Tarik Jasarevic, a WHO spokesperson told STAT that it was “inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments.”

Remdesivir, an experimental drug originally developed to treat Ebola, is not yet approved for that or any other disease. But studies conducted by remdesivir’s maker, Gilead, have shown that the experimental drug could be effective against coronaviruses like those that cause SARS and MERS. So during the COVID-19 crisis, Chinese researchers contacted the company about using it to treat the sickest patients, and Gilead made the drug available under a compassionate use program, to treat those with no other treatment options.

After Gilead agreed, Chinese doctors launched two formal studies of remdesivir; one in severely ill patients, and another in people with milder disease. Both studies compared the drug to a placebo. But in mid-April, both were suspended when scientists could not enroll the more than 400 patients needed for each trial.

The summary posted temporarily to the WHO’s website involved the trial to treat severe patients. The Chinese researchers noted that remdesivir was “not associated with a difference in time to clinical improvement,” according to STAT, which took a screen shot of the study before it was removed. In addition, according to the documentation briefly published on the WHO site, after a month, there was almost no difference in the fatality rate of patients given remdesivir compared to those who received the placebo.

In a statement responding to the results, Dr. Merdad Parsey, chief medical officer of Gilead Sciences, said “we believe the post included inappropriate characterizations of the study. The study was terminated early due to low enrollment and, as a result, it was underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in the disease.”

Parsey seemingly was referencing recent remdesivir studies involving COVID-19 patients in the U.S., Europe and Canada, which have hinted at more positive results. In one, which involved 53 patients who were treated with remdesivir on a compassionate use basis, 68% of those experiencing severe respiratory symptoms improved after 10 days. In another, involving 125 U.S. patients, most who took the drug improved enough to be discharged from the hospital. However, unlike the Chinese studies, those trials did not compare remdesivir to a placebo.

The studies from China would be the first to provide solid data from gold standard clinical trials that randomly assigned people to remdesivir or placebo. Their results would likely guide decisions about ongoing trials in the U.S. and around the world, including one sponsored by Gilead and another by the National Institutes of Health, seeking to uncover which COVID-19 patients might benefit most from the drug, and when in the course of the disease the drug is most effective. Those studies, however, will take months to complete, regardless of this data leak.

Popular posts from this blog

New story in Health from Time: 3 More People Diagnosed With Coronavirus in Northern California

Three more people in Northern California have been diagnosed with the coronavirus known as 2019-nCoV, health officials in the area said Sunday, doubling the number of cases in the state and bringing the total across the country to 11 . The patients, whose symptoms are not yet serious enough to warrant hospitalization, are being kept in their homes, where they are being closely monitored, the San Francisco Chronicle reports . Two of the patients are a husband and wife from San Benito County. The husband fell ill after he returned home from Wuhan, China, where the outbreak began. It is believed he transferred the virus to his wife, who had not been to China. The other patient became sick while visiting family in Santa Clara County. She also previously visited Wuhan. Since arriving in the United States on Jan. 23, she has only left her home twice to seek out medical assistance. Officials from both counties said they are working to identify anyone who may have come into cont...

New video by blogilates on YouTube

Day 8 - 14 | Blogilates 2020 Challenge You guys are CRUSHING the #2020Challenge so far! Idk about you but my abs are soooooore! This week, we're doing 20 reps of abs every day + 20 reps of another new exercise every day! If you need a little extra motivation, text my number (510-692-4556) and tell me all about it so we can come up with a solution together! This link also works: https://ift.tt/2Qjqw7G This week's moves are: Jan. 8th (starts 0:48) - 20 butterfly bridges + 20 criss cross (butt + abs) Jan. 9th (starts 2:43) - 20 oil riggers + 20 rollovers (arms + abs) Jan. 10th (starts 8:29) - 20 lunges + 20 leg outs (legs + abs) Jan. 11th (starts 11:03) - 20 walnut crushers + 20 single leg drops (back + abs) Jan. 12th (starts 13:41) - 20 sprinters + 20 crunches (obliques + abs) Jan. 13th (starts 16:27) - 20 squat jumps + 20 russian twists (cardio + abs) Jan. 14th (starts 18:57) - 20 plank jacks + 20 butt ups (total body + abs) Here is where I get all of my music! Epidemic Sound: ...

New story in Health from Time: Coronavirus Cases Outside China Are Accelerating Rapidly. Here’s What to Know

A surge in deadly coronavirus cases outside China is raising concerns that the outbreak has reached a new stage and could continue its global spread to even more vulnerable countries. In the central Chinese province of Hubei, where the virus is believed to have originated, the number of cases appears to be stabilizing, according to government figures. But the number of people infected elsewhere in the world is rising quickly, with clusters in South Korea , Italy, Iran and a cruise ship docked in Japan. As of Monday, more than 2,200 cases of the virus, officially called COVID-19, have been reported outside of mainland China, where the overwhelming majority of the 79,000 cases have been located since officials first discovered the disease in December. The number of deaths outside China has also increased to 166, including 50 in Iran and four in Italy. In a news conference Monday, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said the WHO...